Logo

Chinese Agency Clears BGI-Complete Genomics Deal

Feb 26, 2013 | staff reporter

NEW YORK (GenomeWeb News) – The Ministry of Commerce of the People's Republic of China has approved BGI's proposed acquisition of Complete Genomics, BGI announced after the close of the market on Monday.

The $118 million deal is still awaiting approval by the China's State Administration of Foreign Exchange. BGI last week extended its cash tender offer for Complete Genomics until midnight ET March 1, as it waited for approval from the two agencies.

BGI's bid for the Mountain View, Calif.-based firm was originally announced in September. The deal cleared US antitrust review in early January.

Filed under

Clinical Sequencing
Sequencing
Diagnostics
Business News
BGI
mergers & acquisitions
Next-Generation Sequencing
MGI Tech
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.